Novel Strategy for Molecular Targeted Therapy in Cancer
A special issue of Molecules (ISSN 1420-3049). This special issue belongs to the section "Medicinal Chemistry".
Deadline for manuscript submissions: closed (30 June 2021) | Viewed by 3841
Special Issue Editor
Special Issue Information
Dear Colleagues,
The completion of the Human Genome Project in 2003 marked the initial transition of biomedical sciences into the post-genomic era. With the growing body of data on genetic alterations on individual tumors, the aspirations of personalized medicine are more rapidly emerging as a tangible reality. True to this framework, precision oncology aims to pinpoint unique genetic vulnerabilities found solely in a patient’s tumor. Off-target side-effects are thus minimized, as these targeted vulnerabilities are absent from other normal tissues.
One of the greatest challenges to realizing the precision oncology approach is the traditional view of what constitutes an “actionable” genetic vulnerability. For instance, the recent success of targeting tumors with NTRK fusions with specific kinase inhibitors has largely led the field to focus on mutant or fusion-activated oncogenes. However, strategies other than this conventionally adopted approach stand to be just as—if not even more—therapeutically effective. Collateral lethality, an approach based on genomic passenger deletions, is just one example of a contrasting therapeutic strategy under the larger umbrella of precision oncology. The multitude of genetic tumor data welcomes the discovery of alternate, innovative approaches that need not be overshadowed by the general trends in the field.
Dr. Florian L MullerGuest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Molecules is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- Targeted therapy
- Cancer genomics
- Cancer metabolism
- Drug design
